Teva President and CEO Shlomo Yanai said last week after presenting second-quarter results that he had good reason to believe his company was close to getting approval for its generic version of Lovenox, but he gave no timeline.
A simple question by analysts as to "what good reason" may have been a valuable contribution to doing their job.
Whenever I see a citation like this, you know it is a PR job and nothing more.
Market Data 
Markets 
AI
